LOUISVILLE, CO, December 19, 2007 – GlobeImmune, Inc. announced today the initiation of the Company’s Phase 2 clinical trial to evaluate GI-5005 Tarmogen® for the treatment of patients with chronic hepatitis C infection. GI-5005 is being evaluated as a potential … Continue reading
GlobeImmune Announces Initiation of Phase 2 Clinical Trial of GI-5005 in Patients with Chronic Hepatitis C
December 19, 2007